Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with 64Cu-labeled trastuzumab PET

被引:41
|
作者
Paudyal, Pramila [1 ,2 ]
Paudyal, Bishnuhari [1 ,2 ]
Hanaoka, Hirofumi
Oriuchi, Noboru [1 ,2 ]
Iida, Yashuhiko
Yoshioka, Hiroki [1 ,2 ]
Tominaga, Hideyuki [1 ,2 ]
Watanabe, Satoshi [3 ]
Watanabe, Shigeki [3 ]
Ishioka, Noriko S. [3 ]
Endo, Keigo [1 ,2 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Diagnost Radiol, Maebashi, Gunma, Japan
[2] Gunma Univ, Grad Sch Med, Dept Nucl Med, Maebashi, Gunma, Japan
[3] Japan Atom Energy Agcy, Quantum Beam Sci Directorate, Takasaki, Gunma, Japan
关键词
PHASE-II TRIAL; BREAST-CANCER; ANTIBODY; GEMCITABINE; CISPLATIN; MICE;
D O I
10.1111/j.1349-7006.2010.01480.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-small cell lung carcinomas (NSCLC) overexpress the Her2/neu gene in approximately 59% of cases. Trastuzumab, a humanized monoclonal antibody, interferes with Her2 signaling and is approved for the treatment of Her2/neu overexpressing breast cancer. However, its therapeutic use in Her2/neu overexpressing NSCLC remains obscure. The present study aimed to determine the role of 64 Cu-labeled trastuzumab positron emission tomography (PET) for non-invasive imaging of Her2/neu expression in NSCLC. Trastuzumab was conjugated with the bifunctional chelator 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA) and radiolabeled with Cu-64. The molecular specificity of DOTA-trastuzumab was determined in NSCLC cell lines with Her2/neu overexpression (NCI-H2170) and negative expression (NCI-H520). Imaging of Her2/neu expression was performed in NCI-H2170 tumor-bearing mice with 64 Cu-DOTA-trastuzumab PET and 64 Cu-DOTA-IgG. In vitro studies revealed specific binding of DOTA-trastuzumab in the Her2/neu positive NCI-H2170 cells, while no binding was seen in the Her2/neu negative NCI-H520 cell line. Biodistribution and PET studies revealed a significantly high accumulation of 64 CuDOTA-trastuzumab in the Her2/neu overexpressing NCI-H2170 tumor at 24 and 48 h post-injection (21.4 +/- 1.4% and 23.2 +/- 5.1% injection dose/gram (% ID/g), respectively). PET imaging of Her2/neu negative NCI-H520 tumors showed much less uptake of 64 CuDOTA- trastuzumab (4.0% ID/g). The NCI-H2170 tumor uptake of 64 Cu-DOTA-trastuzumab was significantly higher than that of 64 Cu-DOTA-IgG (P < 0.0001). 64 Cu-DOTA-trastuzumab showed a very clear image of a Her2/neu positive tumor and appeared to be effective as a PET tracer for imaging of Her2/neu gene expression in NSCLC, suggesting its potential clinical use for identifying patients that might benefit from trastuzumab-based therapy. (Cancer Sci 2010; 101: 1045-1050)
引用
收藏
页码:1045 / 1050
页数:6
相关论文
共 50 条
  • [31] Molecular Characteristics of HER2 Mutations in Non-Small Cell Lung Cancer
    Wei, X.
    Gao, X.
    Zhang, X.
    Chen, Z.
    Wu, Y.
    Zhou, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S848 - S849
  • [32] HER2 Mutations in Chinese Patients with Non-Small Cell Lung Cancer
    Song, Zhengbo
    Zhang, Yiping
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S494 - S495
  • [33] Targeting HER2 genomic alterations in non-small cell lung cancer
    Zeng, Jie
    Ma, Weijie
    Young, Richard Benjamin
    Li, Tianhong
    JOURNAL OF THE NATIONAL CANCER CENTER, 2021, 1 (02): : 58 - 73
  • [34] HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer
    Cappuzzo, F
    Bemis, L
    Varella-Garcia, M
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24): : 2619 - 2621
  • [35] PET Imaging of Dll4 Expression in Glioblastoma and Colorectal Cancer Xenografts Using 64Cu-Labeled Monoclonal Antibody 61B
    Zhou, Bin
    Wang, Hui
    Liu, Ren
    Wang, Mengzhe
    Deng, Huaifu
    Giglio, Benjamin C.
    Gill, Parkash S.
    Shan, Hong
    Li, Zibo
    MOLECULAR PHARMACEUTICS, 2015, 12 (10) : 3527 - 3534
  • [36] HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients
    Altundag, O
    Altundag, K
    Ozcakar, B
    Silay, YS
    LUNG CANCER, 2005, 49 (02) : 279 - 280
  • [37] 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
    Hiroaki Kurihara
    Akinobu Hamada
    Masayuki Yoshida
    Schuichi Shimma
    Jun Hashimoto
    Kan Yonemori
    Hitomi Tani
    Yasuji Miyakita
    Yousuke Kanayama
    Yasuhiro Wada
    Makoto Kodaira
    Mayu Yunokawa
    Harukaze Yamamoto
    Chikako Shimizu
    Kazuhiro Takahashi
    Yasuyoshi Watanabe
    Yasuhiro Fujiwara
    Kenji Tamura
    EJNMMI Research, 5
  • [38] 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
    Kurihara, Hiroaki
    Hamada, Akinobu
    Yoshida, Masayuki
    Shimma, Schuichi
    Hashimoto, Jun
    Yonemori, Kan
    Tani, Hitomi
    Miyakita, Yasuji
    Kanayama, Yousuke
    Wada, Yasuhiro
    Kodaira, Makoto
    Yunokawa, Mayu
    Yamamoto, Harukaze
    Shimizu, Chikako
    Takahashi, Kazuhiro
    Watanabe, Yasuyoshi
    Fujiwara, Yasuhiro
    Tamura, Kenji
    EJNMMI RESEARCH, 2015, 5
  • [39] [64Cu]Cu-NOTA-Trastuzumab and [89Zr]Zr-DFO-Trastuzumab in Xenografts with Varied HER2 Expression
    Simo, Cristina
    Shmuel, Shayla
    Vanover, Alex
    Pereira, Patricia M. R.
    MOLECULAR PHARMACEUTICS, 2024, 21 (12) : 6311 - 6322
  • [40] HER2 copy number variation in non-small cell lung cancer (NSCLC)
    Tagliamento, M.
    Auclin, E.
    Valent, A.
    Ferrara, R.
    Cotteret, S.
    Rouleau, E.
    Caramella, C.
    Melia, M. Riudavets
    Gazzah, A.
    Adam, J.
    Jovelet, C.
    Bayle, A.
    Lacroix, L.
    Auger, N.
    Barlesi, F.
    Planchard, D.
    Besse, B.
    Mezquita, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1050 - S1050